India's drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials told PTI on Friday.
Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of "cytokine'' release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.
"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome," an official told PTI.
"It is already an approved drug of Biocon for treating psoriasis for last many years," the official said.
Written informed consent of each patient is required before the use of this drug, he said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
New XEC Covid Variant Spreads To 27 Countries, Here's What We Know So Far Study Shows How Long Covid Is Debilitating Children's Health From FLiRT To FLuQE: What To Know About The Latest Covid Variants MK Stalin Asks Centre To Recall Tamil Nadu Governor In Row Over Anthem Hamas Searching For Yahya Sinwar's Replacement Outside Gaza: Report Can Hamas Recover After Yahya Sinwar's Killing? What Experts Say 3 Decades Later, First Brown Dwarf Ever Found Offers A Surprise "We Have A Lot Of Interest In Indian Films": Putin Praises Bollywood Sugar Content In Baby Foods Among Issues Under Parliamentary Panel Scanner Track Latest News Live on NDTV.com and get news updates from India and around the world.